NCT01850381 - Phase 2A Study of GM 608 in Mild to Moderate Parkinson Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions

Parkinson's Disease

Interventions

DRUG

GM608

For GM608: 320 mg/dose reconstituted with 6.4 mL bacteriostatic saline. Administer 6.4 mL GM608 dosing solution by intravenous (IV) bolus over 1 min, on Monday, Wednesday, Friday for two consecutive weeks.

DRUG

Placebo Comparator

For Placebo: Administer 6.4 mL Bacteriostatic saline by intravenous (IV) bolus over 1 min, on Monday, Wednesday, Friday for two consecutive weeks.

Trial Locations (1)

10032

Columbia University Medical Center/NY Presbyterian Hospital, New York